Marker Therapeutics, Inc. (MRKR) Stock Price & Analysis
Marker Therapeutics, Inc. (MRKR) — MoonshotScore 19/100 (Weak band), calculated Oct 26, 2026. Price $0.897 (-6.57%), as of the Oct 26, 2026 trading session; market cap $15.0M.
Educational signal · not a buy or sell recommendation · How to read this
Marker Therapeutics, Inc. · MRKR · NASDAQ
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies and peptide-based vaccines. Their MultiTAA-specific T cell technology targets multiple tumor-associated antigens to treat hematological malignancies and solid tumors.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Marker Therapeutics (MRKR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $1M (Q3 FY2025, quarter ended Sep 30, 2025)
- EPS beat 7 of 8
- Altman Z -41.47 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak |
The score moved from 23 in the stored Oct 24, 2026 snapshot to 19 in the current publication computed Oct 26, 2026 (-4); the largest pillar moves were Momentum +5.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.897 | |
| Change on the day | -6.57% | |
| 52-week range | $0.84 – $2.46 | |
| Market capitalisation | $15.0M | |
| Shares traded on the day | 117.9K |
Price & events
Other perspectives
Council score for Marker Therapeutics (MRKR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the MRKR film — every key number, told as a short cinematic story
~2 min · open the film
What is Marker Therapeutics (MRKR), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Marker Therapeutics, Inc. (MRKR) is listed on NASDAQ. It employs 5 people and is led by Juan F. Vera. In Q3 FY2025 it reported revenue of $1M and net income of -$2M. The market values it at $15.0M.
What do the latest results show for Marker Therapeutics (MRKR)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1M. Against analyst estimates the company has EPS beat 7 of 8 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1M | -$2M | -$0.12 (diluted) |
What are the financial strengths and risks for Marker Therapeutics (MRKR)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Altman Z -41.47 · Piotroski F 2. Trailing ratios: ROE -57.0% · ROA -59.7% · current ratio 6.03 · earnings yield -50.6% · free-cash-flow yield -65.7%.
Data-derived red flags
- Listing risk — at $0.897 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -41.47 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-57.0%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Marker Therapeutics (MRKR)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $4.24M · EPS -0.59 · 2 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q3 FY2025) was filed Nov 13, 2025 — 11 months ago.
Checked against the records this page reads, on the dates shown above.
How does Marker Therapeutics compare with its peers?
Short answer
Marker Therapeutics's score ranks 3rd of 3 in the bounded comparison shown, against 2 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.61 Oct 26, 2026 | $125B | 92 5-pillar Oct 26, 2026 | |
| $158.69 Oct 26, 2026 | $193B | 67 5-pillar Oct 26, 2026 | |
| Marker Therapeutics (MRKR) — this page | $0.897 | $15.0M | 19 |
| $4.97 Jun 2, 2025 | $48.7M | — Model unavailable | |
| $16.65 Oct 26, 2026 | $88.5M | — Model unavailable | |
| $10.24 Oct 26, 2026 | $93.6M | — Model unavailable | |
| $4.08 Oct 26, 2026 | $170M | — Model unavailable | |
| $2.44 Oct 26, 2026 | $190M | — Model unavailable | |
| $8.45 Oct 26, 2026 | $252M | — Model unavailable | |
| $8.81 Oct 26, 2026 | $506M | — Model unavailable | |
| $9.53 Oct 26, 2026 | $566M | — Model unavailable | |
| $3.85 Oct 26, 2026 | $570M | — Model unavailable | |
| $7.94 Oct 26, 2026 | $612M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $4.24M
- EPS estimate
- $-0.59
Measured against a quoted price of $0.897 (as of Oct 26, 2026).
Common Questions About MRKR
These answers are editorial: 1 of these 9 answers is drawn from the MRKR research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MRKR?
MRKR carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies and peptide-based vaccines.
Is MRKR a good stock to buy?
Stock Expert AI does not rate MRKR buy, sell or hold. Marker Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MRKR stock price today?
The last price recorded on this page for Marker Therapeutics, Inc. (MRKR) is $0.897, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for MRKR?
Marker Therapeutics faces several risks inherent to clinical-stage biotechnology companies. Clinical trial failures or delays represent a significant risk, as positive results are crucial for regulatory approval and commercialization.
What are the key factors to evaluate for MRKR?
Marker Therapeutics, Inc. (MRKR) holds a MoonshotScore in the low range. Securing such partnerships is crucial for long-term growth and sustainability. Not financial advice.
How frequently does MRKR data refresh on this page?
MRKR's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MRKR's recent stock price performance?
Marker Therapeutics, Inc. (MRKR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary MultiTAA-specific T cell technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRKR overvalued or undervalued right now?
Marker Therapeutics, Inc. (MRKR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of MRKR?
Fractional-share availability for Marker Therapeutics, Inc. (MRKR) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.897 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T15:44:59.632Z. | |
px.change | Change on the day | -6.57% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $15.0M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T15:42:36.000Z. Captured from FMP at 2026-10-26T15:44:58.576Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.0631 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2025 | $1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 117.9K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q3 FY2025 | -$2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 1 quarters through Q3 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -41.47 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
px.range52 | 52-week range | $0.84 – $2.46 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.employees | Employees | 5 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.ceo | Chief executive | Juan F. Vera | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -57.0% · ROA -59.7% · current ratio 6.03 · earnings yield -50.6% · free-cash-flow yield -65.7% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $4.24M · EPS -0.59 · 2 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-23 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $4.24M | UNRECORDED | Stored analyst estimates — Captured 2026-10-23 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-0.59 | UNRECORDED | Stored analyst estimates — Captured 2026-10-23 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 19 of 100 · Weak · pillars 8 / 25 / 20 / 11 / 39 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 23 (stored snapshot Oct 24, 2026) → 19 (current publication computed Oct 26, 2026) (-4) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.